Elite Journal of Laboratory Medicine. Volume 1 issue 1(2023), Pp. 1-12 https://epjournals.com/journals/EJLM

Treatment Strategies for Aplastic Anemia in HIV: Current Approaches and Future Directions

*Emmanuel Ifeanyi Obeagu[1]

[1]Department of Medical Laboratory Science, Kampala International University, Uganda

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Aplastic anemia (AA) poses a significant hematologic challenge characterized by bone marrow failure and peripheral blood pancytopenia. In the context of HIV infection, managing AA presents unique complexities, necessitating tailored treatment strategies to address the intricate interplay between immune dysregulation, viral pathogenesis, and hematopoietic suppression. This review provides a comprehensive overview of current treatment approaches for AA in HIV, ranging from traditional immunosuppressive therapies to emerging immunomodulatory agents and hematopoietic stem cell transplantation (HSCT). Additionally, it explores future directions in AA management, highlighting promising therapeutic avenues and ongoing research aimed at enhancing clinical outcomes in affected individuals. Understanding the evolving landscape of AA treatment in the setting of HIV infection is crucial for optimizing patient care and advancing therapeutic interventions in this challenging clinical scenario.

Keywords: *Aplastic Anemia, HIV, Treatment Strategies, Immunosuppression, Hematopoietic Stem Cell Transplantation, Immunomodulatory Therapies*

Introduction

Aplastic anemia (AA) stands as a formidable hematologic challenge, characterized by the failure of bone marrow to produce an adequate number of blood cells, resulting in peripheral blood pancytopenia. While AA is relatively rare, its clinical impact is profound, necessitating a nuanced understanding of its pathogenesis and therapeutic management. In the context of human immunodeficiency virus (HIV) infection, the management of AA becomes even more complex, as the interplay between immune dysregulation and hematopoietic suppression adds layers of

Citation: Obeagu EI. Treatment Strategies for Aplastic Anemia in HIV: Current Approaches and Future Directions. Elite Journal of Laboratory Medicine, 2023; 1(1): 1-12

intricacy to disease progression and treatment strategies. The pathogenesis of AA involves a delicate balance between immune regulation and hematopoietic homeostasis. Immune dysregulation, characterized by aberrant immune responses targeting hematopoietic stem cells (HSCs) within the bone marrow, plays a central role in the development of AA. In individuals coinfected with HIV, the immunological landscape is further complicated by chronic immune activation, CD4+ T cell depletion, and dysregulated cytokine signaling, creating a milieu conducive to hematopoietic suppression and bone marrow failure.[1-10]

Traditional treatment approaches for AA in HIV-infected individuals often revolve around immunosuppressive therapies aimed at suppressing aberrant immune responses while preserving immune function against opportunistic infections. However, challenges such as the risk of infectious complications and the potential for relapse following treatment discontinuation underscore the need for alternative therapeutic strategies and optimization of treatment protocols. Hematopoietic stem cell transplantation (HSCT) represents a curative option for eligible AA patients, including those with HIV coinfection. With advancements in transplantation techniques and supportive care, HSCT outcomes have improved significantly, offering hope for long-term hematopoietic recovery. However, the selection of suitable donors and the management of post-transplant complications, particularly in the context of HIV, remain areas of active research and clinical optimization. Emerging immunomodulatory therapies, including anti-cytokine therapies and immune checkpoint inhibitors, hold promise in ameliorating immune dysregulation in AA and HIV. Targeting dysregulated cytokine signaling pathways and immune checkpoints offers potential avenues for modulating immune responses while minimizing off-target effects. Furthermore, collaborative efforts between clinicians, researchers, and pharmaceutical stakeholders are imperative for translating scientific insights into clinically meaningful interventions and addressing the unmet needs of this vulnerable patient population.[11-20]

In this review, it aims to provide a comprehensive overview of current treatment strategies for AA in the context of HIV infection, encompassing both established approaches and emerging therapeutic modalities.

Current Treatment Approaches

Current treatment approaches for aplastic anemia (AA) in the context of HIV infection encompass a multidisciplinary approach aimed at addressing the underlying immunological dysregulation while managing the complications of both conditions. Traditional treatment strategies for AA in HIV-infected individuals often involve immunosuppressive therapies to suppress aberrant immune responses targeting hematopoietic stem cells (HSCs). The combination of anti-thymocyte globulin (ATG) and cyclosporine is commonly used to induce hematopoietic recovery by modulating immune function. However, careful monitoring for infectious complications, including opportunistic infections, is essential due to the risk of immunosuppression. Supportive care measures play a crucial role in managing AA in HIV-infected individuals, including blood transfusions to address cytopenias and prevent complications such as anemia-related fatigue and infection. Additionally, prophylactic antibiotics and antifungals may be administered to mitigate

the risk of opportunistic infections, particularly in patients undergoing immunosuppressive therapy.[21-30]

Hematopoietic Stem Cell Transplantation (HSCT) represents a curative option for eligible AA patients, including those with HIV coinfection. Advances in transplantation techniques and supportive care have improved outcomes, but challenges remain, including donor selection, graft-versus-host disease (GVHD), and post-transplant infectious complications. Nonetheless, HSCT offers the potential for long-term hematopoietic recovery and immune reconstitution in HIV-infected individuals with AA. Emerging immunomodulatory therapies hold promise in ameliorating immune dysregulation in AA and HIV. Targeting dysregulated cytokine signaling pathways, such as interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α), offers potential avenues for modulating immune responses while minimizing off-target effects. Additionally, immune checkpoint inhibitors aim to unleash anti-tumor immunity and promote hematopoietic recovery in AA patients, including those with HIV coinfection. Effective management of HIV infection with antiretroviral therapy (ART) is paramount in HIV-infected individuals with AA. Suppression of HIV viral replication not only reduces the risk of opportunistic infections but also contributes to immune reconstitution and may enhance the efficacy of AA treatment modalities, including immunosuppressive therapies and HSCT.[31-50]

Hematopoietic Stem Cell Transplantation (HSCT)

Hematopoietic stem cell transplantation (HSCT) stands as a curative option for eligible individuals with aplastic anemia (AA), including those coinfected with HIV. This therapeutic modality involves the infusion of hematopoietic stem cells, either from a matched related donor, matched unrelated donor, or alternative donor source, with the aim of restoring hematopoietic function and immune competence. In the context of HIV infection, HSCT offers the potential for long-term hematopoietic recovery and immune reconstitution, albeit with unique challenges and considerations. The selection of appropriate candidates for HSCT in the setting of HIV requires careful consideration of multiple factors, including HIV disease status, viral load, CD4+ T-cell count, comorbidities, and availability of suitable donors. Pre-transplant evaluation encompasses comprehensive assessment of HIV disease control, screening for opportunistic infections, and optimization of antiretroviral therapy to achieve viral suppression and immune reconstitution prior to transplantation. Donor selection for HSCT in HIV-infected individuals follows established criteria, with preference given to HLA-matched related donors or matched unrelated donors. Alternative donor sources, including haploidentical donors and umbilical cord blood units, may be considered in the absence of suitable matched donors. The choice of graft source depends on donor availability, patient age, comorbidities, and transplant center expertise.[51-55]

The conditioning regimen used in HSCT for AA in HIV-infected individuals typically consists of a combination of chemotherapy and/or total body irradiation to suppress the recipient's immune system and create a favorable environment for donor stem cell engraftment. Reduced-intensity conditioning regimens, which aim to minimize toxicity while preserving graft-versus-tumor effects, are commonly employed in this population to reduce the risk of transplant-related

complications. Following HSCT, close monitoring and supportive care are essential to optimize transplant outcomes and minimize the risk of complications. Management of graft-versus-host disease (GVHD), infections, and immune reconstitution syndrome (IRIS) are paramount in HIV-infected recipients. Immunosuppressive therapy may be required to prevent or treat GVHD while preserving graft function and minimizing infectious risks. Long-term follow-up of HIV-infected individuals undergoing HSCT includes monitoring of HIV viral load, CD4+ T-cell count, and immune reconstitution. Achieving sustained viral suppression and immune reconstitution post-transplant are critical for minimizing the risk of HIV-related complications and optimizing overall survival. Additionally, screening for late effects of transplantation, including secondary malignancies and end-organ dysfunction, is essential for comprehensive post-transplant care.[56-60]

Emerging Immunomodulatory Therapies

Emerging immunomodulatory therapies hold promise in the management of aplastic anemia (AA) in individuals with HIV infection, offering alternative treatment options to traditional immunosuppressive regimens. These novel therapies aim to target dysregulated immune responses while minimizing off-target effects and preserving immune function. Several promising approaches are currently under investigation: Dysregulated cytokine signaling, particularly elevated levels of interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α), play a central role in the pathogenesis of AA and HIV-related immune dysregulation. Anti-cytokine therapies, including monoclonal antibodies and small molecule inhibitors, offer potential avenues for modulating immune responses and ameliorating marrow destruction in affected individuals. By targeting specific cytokines implicated in AA and HIV pathogenesis, these therapies aim to restore immune homeostasis and promote hematopoietic recovery. Immune checkpoint inhibitors, such as antibodies targeting programmed cell death protein 1 (PD-1) and its ligands (PD-L1/PD-L2), have revolutionized cancer immunotherapy by unleashing anti-tumor immune responses. In the context of AA and HIV, immune checkpoint inhibitors hold promise in overcoming immune exhaustion and restoring immune surveillance against aberrant hematopoietic cells. By blocking inhibitory signals that dampen T cell function, these agents aim to enhance immune-mediated clearance of infected or dysregulated cells, thereby promoting hematopoietic reconstitution and immune reconstitution.[61-70]

Regulatory T cells (Tregs) play a crucial role in maintaining immune tolerance and preventing autoimmunity. Dysregulation of Treg function has been implicated in the pathogenesis of AA and HIV-related immune dysregulation. Treg therapy, involving the adoptive transfer of ex vivo expanded Tregs or the induction of endogenous Treg expansion, offers a promising approach to restoring immune balance and suppressing aberrant immune responses in affected individuals. By enhancing immune regulation and dampening inflammatory responses, Treg therapy may mitigate immune-mediated marrow destruction and promote hematopoietic recovery in AA patients with HIV coinfection. Advances in our understanding of the molecular pathways involved in AA and HIV pathogenesis have paved the way for targeted immunomodulatory approaches. These include therapies aimed at modulating specific immune cell subsets, signaling pathways, or cytokine networks implicated in disease pathogenesis. By selectively targeting key mediators of immune

dysregulation, these therapies offer the potential for more precise and efficacious treatment of AA in the context of HIV infection, with reduced off-target effects and improved therapeutic outcomes.[71-75]

Conclusion

The emergence of novel immunomodulatory therapies holds significant promise for advancing the management of aplastic anemia (AA) in individuals with HIV infection. These therapies offer alternative approaches to traditional immunosuppressive regimens, aiming to target dysregulated immune responses while preserving immune function and promoting hematopoietic recovery. Anti-cytokine therapies, immune checkpoint inhibitors, regulatory T cell (Treg) therapy, and targeted immunomodulation represent key avenues for intervention, leveraging our growing understanding of the immunopathogenesis of AA and HIV-related immune dysregulation. By selectively targeting key mediators of immune dysregulation, such as cytokines and immune checkpoint molecules, these therapies offer the potential for more precise and efficacious treatment, with reduced off-target effects and improved therapeutic outcomes. Additionally, the integration of emerging immunomodulatory therapies into multimodal treatment approaches, including combination regimens and personalized treatment strategies, may further enhance their efficacy and clinical utility in affected individuals.

References

1. Sankar V, Villa A. Hematologic diseases. Burket's Oral Medicine. 2021:627-664.
2. Weinzierl EP, Arber DA. The differential diagnosis and bone marrow evaluation of new-onset pancytopenia. American journal of clinical pathology. 2013;139(1):9-29.
3. Smith JN, Kanwar VS, MacNamara KC. Hematopoietic stem cell regulation by type I and II interferons in the pathogenesis of acquired aplastic anemia. Frontiers in Immunology. 2016; 7:217479.
4. Storb RF, Lucarelli G, McSweeney PA, Childs RW. Hematopoietic cell transplantation for benign hematological disorders and solid tumors. ASH Education Program Book. 2003;2003(1):372-397.
5. Volberding PA, Baker KR, Levine AM. Human immunodeficiency virus hematology. ASH Education Program Book. ;2003(1):294-313.
6. Blood GA. Human immunodeficiency virus (HIV). Transfusion Medicine and Hemotherapy. 2016;43(3):203.
7. Parekh BS, Ou CY, Fonjungo PN, Kalou MB, Rottinghaus E, Puren A, Alexander H, Hurlston Cox M, Nkengasong JN. Diagnosis of human immunodeficiency virus infection. Clinical microbiology reviews. 2018;32(1):10-128.
8. Opie J. Haematological complications of HIV infection: forum-review. South African Medical Journal. 2012;102(6):465-468.

Citation: Obeagu EI. Treatment Strategies for Aplastic Anemia in HIV: Current Approaches and Future Directions. Elite Journal of Laboratory Medicine, 2023; 1(1): 1-12

9. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. Madonna University journal of Medicine and Health Sciences. 2022;2(3):120-127.
10. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023 ;3(1):7-12. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91.
11. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. J Pub Health Nutri. 2023; 6 (2). 2023; 141:1-2. links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf.
12. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
13. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. Int J Curr Res Med Sci. 2017;3(1): 21-38.DOI: 10.22192/ijcrms.2017.03.01.004
14. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;129. links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf.
15. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
16. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
17. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. Journal of Pharmaceutical Research International. 2020;32(22):101-119.
18. Obeagu EI, Eze VU, Alaeboh EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016; 5:464-471. links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf.
19. Gandhi S, Abuarqoub H, Kordasti S, Jiang J, Kulasekararaj A, Mufti G, Marsh JC. Pathology of bone marrow failure syndromes. Diagnostic Histopathology. 2015;21(5):174-180.
20. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-916.

https://www.academia.edu/download/38320140/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma2.EMMA1.pdf.

21. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res. Biol. Sci. 2016;3(10): 55-65.DOI; 10.22192/ijarbs.2016.03.10.009
22. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75. links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf
23. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences. 2022;2(3):110-119.
24. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30. links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf.
25. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144. https://www.academia.edu/download/38320159/Obeagu_Emmanuel_Ifeanyi3__et_al.IJCRAR.pdf.
26. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4. links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf
27. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
28. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
29. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139. links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf.

Citation: Obeagu EI. Treatment Strategies for Aplastic Anemia in HIV: Current Approaches and Future Directions. Elite Journal of Laboratory Medicine, 2023; 1(1): 1-12

30. Bonadies N, Rovó A, Porret N, Bacher U. When should we think of myelodysplasia or bone marrow failure in a thrombocytopenic patient? A practical approach to diagnosis. Journal of clinical medicine. 2021;10(5):1026.
31. Groarke EM, Young NS, Calvo KR. Distinguishing constitutional from acquired bone marrow failure in the hematology clinic. Best Practice & Research Clinical Haematology. 2021;34(2):101275.
32. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-134. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86.
33. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022:29-34.
34. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.
35. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137. links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf.
36. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. Int. J. Adv. Res. Biol. Sci. 2023;10(9):135-142.DOI: 10.22192/ijarbs.2023.10.09.015 links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf
37. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. Int. J. Adv. Res. Biol. Sci. 2023;10(9):128-134.DOI: 10.22192/ijarbs.2023.10.09.014 links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf.
38. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfected with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2017;3(5):100-104.DOI: 10.22192/ijcrms.2017.03.05.014 https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf
39. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria

Metropolis, Kaduna State, Nigeria. South Asian Journal of Research in Microbiology. 2022;13(2):26-31.

40. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. J Clin Commun Med. 2020;2(3):180-183.DOI: **DOI:** 10.32474/JCCM.2020.02.000137 links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf.
41. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. Journal of Pharmaceutical Research International. 2021;33(47A):78-84.
42. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023 Jul 29;6(1):203-211. http://research.sdpublishers.net/id/eprint/2819/.
43. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International. 2021;33(57A):360-368.
44. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences. 2022;2(3):6-15. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69
45. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. European Journal of Pharmaceutical and Medical Research, 2023; 10(8): 564-568
46. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETRQVIRAL THERAPY. World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4(3): 153-160**.** links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETRQVIRAL-THERAPY.pdf.
47. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. Int. J. Curr. Res. Biosci. Plant Biol. 2015;2(4):45-49.
48. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. Int. J. Curr. Res. Chem. Pharm. Sci. 2019;6(12):45-8.DOI: 10.22192/ijcrcps.2019.06.12.004

links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf.

49. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. Int. J. Curr. Res. Med. Sci. 2023;9(2):6-13.DOI: 10.22192/ijcrms.2023.09.02.002 links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf.
50. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2016;2(4):29-33. links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf.
51. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. Int. J. Curr. Microbiol. App. Sci. 2015;4(4):906-910. https://www.academia.edu/download/38320134/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma.EMMA2.pdf.
52. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. Int. J. Curr. Res. Biol. Med. 2016;1(2):1-5.
53. Ibebuike JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research,* 2018; 1 (2):08-14. https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf.
54. Wilson CS, Brynes RK. Evaluation of anemia, leukopenia, and thrombocytopenia. Hematopathology E-Book. 2010:154.
55. DeZern AE, Churpek JE. Approach to the diagnosis of aplastic anemia. Blood Advances. 2021;5(12):2660-2671.
56. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parametrs in HIV patients before receiving treatment in Aba, Abia State, Nigeria. Res J Pharma Biol Chem Sci. 2014; 5:825-830.
57. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. International Journal of Life Science, Biotechnology and Pharama Research. 2014; 391:186-189.
58. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023; 3 (1): 7-12.
59. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. International Journal of Innovative and Applied Research. 2022;10(5):1-11.
60. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutase, vitamins

C and E in HIV infected children in Umuahia, Abia state. International Journal of Advanced Research in Biological Sciences. 2015;2(11):268-271.
61. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. Int. J. Curr. Res. Med. Sci. 2018;4(2):104-108.
62. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. Int. J. Adv. Res. Biol. Sci. 2018;5(6):60-66.
63. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. Arch Blood Transfus Disord. 2018;1(2).
64. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75.
65. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
66. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. Medicine (Baltimore). 2023;102(49): e36599. doi: 10.1097/MD.0000000000036599. PMID: 38065920; PMCID: PMC10713174.
67. Anyiam AF, Arinze-Anyiam OC, Irondi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. Medicine (Baltimore). 2023;102(47): e36342. doi: 10.1097/MD.0000000000036342. PMID: 38013335; PMCID: PMC10681551.
68. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. Medicine (Baltimore). 2023;102(47): e35910. doi: 10.1097/MD.0000000000035910. PMID: 38013350; PMCID: PMC10681510.
69. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. Medicine (Baltimore). 2023;102(46): e36166. doi: 10.1097/MD.0000000000036166. PMID: 37986340; PMCID: PMC10659731.
70. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR,
71. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(11):14-25.
72. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. Int. J. Adv. Multidiscip. Res. 2023;10(10):56-62.
73. Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA. Diagnosis and management of AML in

adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood, The Journal of the American Society of Hematology. 2022;140(12):1345-1377.
74. Acevedo A, Alférez S, Merino A, Puigví L, Rodellar J. Automatic recognition system of nucleated peripheral blood cell images. Int. J. Lab. Hematol. 2016; 38:1-.
75. Yusuf AA, Musa BM, Galadanci NA, Babashani M, Mohammed AZ, Ingles DJ, Fogo AB, Wester CW, Aliyu MH. HIV-associated nephropathy: Protocol and rationale for an exploratory genotype-phenotype study in a sub-Saharan African population. Plos one. 2021;16(4):e0249567.